Socrates E Papapoulos

List of Publications by Year in Descending Order

127 papers	11,143 citations	50 h-index	105 g-index
130 ext. papers	12,308 ext. citations	6.5 avg, IF	6.05 L-index

#	Paper	IF	Citations
127	Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥70 years of age in routine primary care across 8 countries in Europe.. *Archives of Osteoporosis*, **2022**, 17, 20	2.9	0
126	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. *Journal of Bone and Mineral Research*, **2021**, 36, 1225-1234	6.3	2
125	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e4155-e4162	5.6	6
124	Impact microindentation measurements correlate with cortical bone material properties measured by Fourier transform infrared imaging in humans. *Bone*, **2020**, 137, 115437	4.7	2
123	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. *Bone*, **2020**, 138, 115478	4.7	13
122	Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption. *Bone*, **2020**, 138, 115512	4.7	4
121	Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective. *Bone*, **2020**, 134, 115244	4.7	5
120	Impact microindentation assesses subperiosteal bone material properties in humans. *Bone*, **2020**, 131, 115110	4.7	9
119	Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 6069-6078	5.6	24
118	Familial Paget's disease of bone: Long-term follow-up of unaffected relatives with and without Sequestosome 1 mutations. *Bone*, **2019**, 128, 115044	4.7	4
117	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2443-2452	5.6	23
116	Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. *Current Medical Research and Opinion*, **2019**, 35, 2097-2102	2.5	11
115	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. *Journal of Bone and Mineral Research*, **2019**, 34, 2220-2228	6.3	64
114	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 899-911	18.1	61
113	New Bone-Forming Agents **2019**, 85-93		
112	Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments. *Bone*, **2018**, 111, 36-43	4.7	8
111	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 2949-2957	5.6	90

110	Fracture Liaison Service **2018**, 405-411		2
109	Adverse Effects of Drugs for Osteoporosis **2018**, 579-587		
108	Future Therapies **2018**, 603-609		
107	Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. *Nature Reviews Endocrinology*, **2018**, 14, 605-623	15.2	23
106	Paget's disease of bone. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2018**, 32, 657-668	6.5	29
105	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. *Journal of Bone and Mineral Research*, **2017**, 32, 1481-1485	6.3	17
104	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 513-523	18.1	419
103	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. *European Journal of Endocrinology*, **2017**, 176, 677-683	6.5	54
102	Impact Microindentation: Consistency of Serial Measurements and Alterations in Patients With Paget's Disease of the Tibia. *Journal of Bone and Mineral Research*, **2017**, 32, 2375-2380	6.3	11
101	Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. *BMC Musculoskeletal Disorders*, **2017**, 18, 174	2.8	8
100	Sclerostin deficiency in humans. *Bone*, **2017**, 96, 51-62	4.7	54
99	Circulating Sclerostin in Bone Sclerosing Disorders. *Biomarkers in Disease*, **2017**, 221-237		
98	Bone: Romosozumab - getting there but not quite yet. *Nature Reviews Endocrinology*, **2016**, 12, 691-692	15.2	4
97	Sclerostin Inhibition in the Management of Osteoporosis. *Calcified Tissue International*, **2016**, 98, 370-80	3.9	54
96	From disease to treatment: from rare skeletal disorders to treatments for osteoporosis. *Endocrine*, **2016**, 52, 414-26	4	19
95	Long-Term Efficacy and Safety of Treatments for Osteoporosis **2016**, 203-232		
94	Circulating Sclerostin in Bone Sclerosing Disorders. *Exposure and Health*, **2016**, 1-18	8.8	
93	Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. *Drugs*, **2015**, 75, 1049-58	12.1	56

92	Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis. *Nature Reviews Endocrinology*, **2015**, 11, 69-70	15.2	24
91	Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment. *PLoS ONE*, **2015**, 10, e0140986	3.7	14
90	Sclerostin deficiency is linked to altered bone composition. *Journal of Bone and Mineral Research*, **2014**, 29, 2144-51	6.3	44
89	Novel approaches to the treatment of osteoporosis. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2014**, 28, 843-57	6.5	24
88	Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations. *BoneKEy Reports*, **2014**, 3, 523		4
87	Olav Bijvoet 1928-2014. *Journal of Bone and Mineral Research*, **2014**, 29, 2527-8	6.3	
86	Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *Journal of Bone and Mineral Research*, **2014**, 29, 1-23	6.3	935
85	The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 4483-92	5.6	202
84	Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. *Journal of Bone and Mineral Research*, **2013**, 28, 848-54	6.3	89
83	Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches. *Best Practice and Research in Clinical Rheumatology*, **2013**, 27, 805-20	5.3	9
82	Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 3873-83	5.6	75
81	Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. *Journal of Bone and Mineral Research*, **2012**, 27, 694-701	6.3	235
80	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. *Bone*, **2012**, 50, 1130-4	4.7	24
79	Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. *Bone*, **2012**, 51, 153-7	4.7	49
78	Low-energy fractures of the humeral shaft and bisphosphonate use. *Journal of Bone and Mineral Research*, **2012**, 27, 1425-31	6.3	7
77	Inhibition of cathepsin K for treatment of osteoporosis. *Current Osteoporosis Reports*, **2012**, 10, 73-9	5.4	81
76	Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. *Bone*, **2011**, 48, 966-71	4.7	145
75	Pharmacology of bisphosphonates. *Bone*, **2011**, 49, 42-9	4.7	148

74	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. *Nature Genetics*, **2011**, 43, 685-9	36.3	134
73	Use of bisphosphonates in the management of postmenopausal osteoporosis. *Annals of the New York Academy of Sciences*, **2011**, 1218, 15-32	6.5	16
72	No effect of rosuvastatin in the zoledronate-induced acute-phase response. *Calcified Tissue International*, **2011**, 88, 402-8	3.9	15
71	Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. *Journal of Bone and Mineral Research*, **2011**, 26, 2804-11	6.3	103
70	The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2441-9	5.6	61
69	Targeting sclerostin as potential treatment of osteoporosis. *Annals of the Rheumatic Diseases*, **2011**, 70 Suppl 1, i119-22	2.4	50
68	Bisphosphonate therapy in children with secondary osteoporosis. *Hormone Research in Paediatrics*, **2011**, 76 Suppl 1, 24-7	3.3	12
67	Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis. *Expert Review of Endocrinology and Metabolism*, **2010**, 5, 711-722	4.1	3
66	Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. *Bone*, **2010**, 47, 169-80	4.7	212
65	The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. *Human Genetics*, **2010**, 128, 615-26	6.3	49
64	First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. *Human Mutation*, **2010**, 31, E1526-43	4.7	44
63	Glucocorticoids are not always deleterious for bone. *Journal of Bone and Mineral Research*, **2010**, 25, 2796-800	6.3	26
62	Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. *Journal of Bone and Mineral Research*, **2010**, 25, 2592-605	6.3	36
61	Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *Journal of Bone and Mineral Research*, **2010**, 25, 2267-94	6.3	840
60	Treatment of Male Osteoporosis with Bisphosphonates **2010**, 667-679		
59	Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. *Journal of Bone and Mineral Research*, **2009**, 24, 1736-40	6.3	107
58	Bisphosphonates: how do they work?. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2008**, 22, 831-47	6.5	88
57	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. *Bone*, **2008**, 42, 841-7	4.7	166

56	Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. *Nature Clinical Practice Endocrinology and Metabolism*, **2008**, 4, 514-23		30
55	SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling **2008**, 139-152		5
54	Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget℞ Disease of Bone. *Calcified Tissue International*, **2008**, 83, 34-42	3.9	34
53	SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. *Developmental Dynamics*, **2007**, 236, 606-12	2.9	36
52	Prolonged bisphosphonate release after treatment in children. *New England Journal of Medicine*, **2007**, 356, 1075-6	59.2	147
51	Determinants of bone strength and clinical practice; effects of bisphosphonates. *Bone*, **2007**, 41, S3-S7	4.7	1
50	Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. *Journal of Bone and Mineral Research*, **2007**, 22, 19-28	6.3	202
49	Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget℞ disease?. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 252-3		
48	Acquired resistance to bisphosphonates in Paget℞ disease of bone. *Journal of Bone and Mineral Research*, **2006**, 21 Suppl 2, P88-91	6.3	26
47	Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor. *Bone*, **2006**, 38, 167-71	4.7	15
46	Bisphosphonate actions: physical chemistry revisited. *Bone*, **2006**, 38, 613-6	4.7	66
45	SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. *Cytokine and Growth Factor Reviews*, **2005**, 16, 319-27	17.9	289
44	Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. *Clinical Pharmacokinetics*, **2005**, 44, 551-70	6.2	171
43	Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. *Journal of Bone and Mineral Research*, **2005**, 20, 1543-7	6.3	41
42	Who will benefit from antiresorptive treatment (bisphosphonates)?. *Best Practice and Research in Clinical Rheumatology*, **2005**, 19, 965-73	5.3	5
41	Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. *Osteoporosis International*, **2005**, 16, 468-74	5.3	107
40	Bone mineral density in sclerosteosis; affected individuals and gene carriers. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 6392-5	5.6	140
39	Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. *FASEB Journal*, **2005**, 19, 1842-4	0.9	709

38	Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. *Journal of Experimental Medicine*, **2004**, 199, 805-14	16.6	691
37	Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study. *Journal of Bone and Mineral Research*, **2004**, 19, 566-70	6.3	49
36	Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. *Journal of Rheumatology*, **2004**, 31, 1732-7	4.1	6
35	Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. *Journal of Bone and Mineral Research*, **2003**, 18, 868-75	6.3	29
34	Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. *Bone*, **2003**, 33, 831-831	4.7	
33	Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. *Bone*, **2003**, 33, 831-8	4.7	17
32	A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. *American Journal of Medical Genetics Part A*, **2002**, 110, 144-52		253
31	A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. *European Journal of Clinical Pharmacology*, **2002**, 57, 883-90	2.8	58
30	Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. *Journal of Bone and Mineral Research*, **2002**, 17, 1057-64	6.3	59
29	Management of malignancy-associated hypercalcemia. *Clinical Reviews in Bone and Mineral Metabolism*, **2002**, 1, 65-76	2.5	1
28	Pharmacological management of Paget's disease of bone. *Clinical Reviews in Bone and Mineral Metabolism*, **2002**, 1, 149-158	2.5	7
27	Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. *Journal of Bone and Mineral Research*, **2001**, 16, 1077-91	6.3	107
26	Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. *Laboratory Investigation*, **2001**, 81, 5-15	5.9	51
25	Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. *Cancer*, **2000**, 88, 3047-3053	6.4	44
24	A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 3713-20	5.6	76
23	The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. *Journal of Bone and Mineral Research*, **1999**, 14, 722-9	6.3	180
22	Interleukin-17: A new bone acting cytokine in vitro. *Journal of Bone and Mineral Research*, **1999**, 14, 1513-21	6.3	134
21	Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. *Osteoporosis International*, **1999**, 10, 259-64	5.3	517

20	Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. *Biochemical and Biophysical Research Communications*, **1999**, 255, 491-4	3.4	170
19	Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. *Biochemical and Biophysical Research Communications*, **1999**, 264, 108-11	3.4	414
18	IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice. *Journal of Bone and Mineral Research*, **1998**, 13, 185-94	6.3	36
17	Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. *Medicine (United States)*, **1997**, 76, 266-83	1.8	196
16	Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. *Baillieres Clinical Endocrinology and Metabolism*, **1997**, 11, 117-43		32
15	Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. *Journal of Bone and Mineral Research*, **1996**, 11, 1492-7	6.3	72
14	Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. *Arthritis and Rheumatism*, **1996**, 39, 396-402		214
13	Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. *Journal of Bone and Mineral Research*, **1995**, 10, 956-62	6.3	122
12	In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. *Journal of Bone and Mineral Research*, **1995**, 10, 1523-30	6.3	34
11	Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate. *Journal of Bone and Mineral Research*, **1994**, 9, 241-6	6.3	1
10	Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. *Journal of Bone and Mineral Research*, **1994**, 9, 1021-8	6.3	38
9	Structural requirements for bisphosphonate actions in vitro. *Journal of Bone and Mineral Research*, **1994**, 9, 1875-82	6.3	100
8	Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. *Journal of Bone and Mineral Research*, **1993**, 8, 175-82	6.3	39
7	The role of bisphosphonates in the prevention and treatment of osteoporosis. *American Journal of Medicine*, **1993**, 95, 48S-52S	2.4	45
6	Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. *Journal of Bone and Mineral Research*, **1992**, 7, 981-6	6.3	22
5	Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. *Journal of Bone and Mineral Research*, **1991**, 6, 1203-10	6.3	21
4	The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. *Cancer*, **1991**, 68, 642-7	6.4	29
3	Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. *Journal of Bone and Mineral Research*, **1989**, 4, 775-81	6.3	54

2	Chapter 49. Bisphosphonates for Postmenopausal Osteoporosis237-241	4
1	Bisphosphonates for Postmenopausal Osteoporosis412-419	2